BMS Terminates Immatics Allogeneic Program Collaboration
Ticker: IMTX · Form: 6-K · Filed: Dec 13, 2024 · CIK: 1809196
Sentiment: bearish
Topics: collaboration-termination, pipeline, licensing
Related Tickers: BMY
TL;DR
BMS is out on Immatics' allogeneic programs, citing portfolio review.
AI Summary
On December 12, 2024, Bristol Myers Squibb (BMS) informed Immatics N.V. that it is terminating its collaboration agreements related to allogeneic programs. This decision stems from BMS's ongoing portfolio prioritization efforts. The agreements in question were dated June 1, 2022, and April 28, 2023.
Why It Matters
This termination by a major pharmaceutical partner like Bristol Myers Squibb could significantly impact Immatics' development pipeline and future revenue streams from this specific collaboration.
Risk Assessment
Risk Level: medium — The termination of a collaboration by a major partner introduces uncertainty regarding future revenue and the progression of specific development programs.
Key Players & Entities
- Bristol Myers Squibb (company) — Terminating party
- Immatics N.V. (company) — Company receiving termination notice
- Celgene Switzerland LLC (company) — Party to the original collaboration agreement
- Immatics US, Inc. (company) — Party to the original collaboration agreement
- June 1, 2022 (date) — Date of initial collaboration agreement
- April 28, 2023 (date) — Date of opt-in agreement
FAQ
What specific allogeneic programs are affected by the termination?
The filing states the termination relates to 'allogeneic programs' but does not specify individual programs by name.
What are the financial implications for Immatics N.V. due to this termination?
The filing does not specify the financial implications, only that BMS is terminating the collaboration due to portfolio prioritization.
Did Immatics N.V. have any recourse or negotiation options after BMS's notification?
The filing states BMS 'notified' Immatics and 'elected to terminate,' implying the decision was made by BMS.
What is the effective date of the termination?
The filing does not specify an effective date for the termination, only the date BMS notified Immatics (December 12, 2024).
Does this termination affect other collaborations Immatics N.V. has with Bristol Myers Squibb or its subsidiaries?
The filing specifically mentions the termination of agreements relating to 'allogeneic programs' and does not indicate if other collaborations are affected.
Filing Stats: 323 words · 1 min read · ~1 pages · Grade level 12.1 · Accepted 2024-12-13 16:13:21
Key Financial Figures
- $60 million — obligated to refund BMS any part of the $60 million upfront payment received under the coll
- $15 million — nder the collaboration agreement or the $15 million opt-in payment received under the opt-i
Filing Documents
- dp222112_6k.htm (6-K) — 11KB
- 0000950103-24-017762.txt ( ) — 12KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. IMMATICS N.V. Date: December 13, 2024 By: /s/ Harpreet Singh Name: Harpreet Singh Title: Chief Executive Officer